Resource Hub

ABHI & DTN Position on Insulin Pumps

Topic : Type : Briefing

The COVID-19 pandemic has impacted all diabetes outpatient services, but in particular, the uptake of diabetes technology. Access to start insulin pump therapy (continuous subcutaneous insulin infusion CSII) or continuous glucose monitoring, has been reduced. This has affected those starting these therapies for the first time as well as those who were due to have renewals because their devices were out of warranty.

A joint position paper from Diabetes Technology Network (DTN) and the Association of British HealthTech Industries (ABHI) on supporting the management of people with diabetes using out-of-warranty pumps, while ensuring appropriate patient choice, can be downloaded below.